Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis) (GPBA)

• ClinicalTrials.gov Identifier: NCT02323100
• Recruitment Status: Recruiting
• First Posted: December 23, 2014
• Last Update Posted: July 15, 2019
• Sponsor: National Jewish Health
• Collaborators: University of Alabama at Birmingham; Children's Hospital of Philadelphia; Johns Hopkins University; Horizon Pharma Ireland, Ltd., Dublin Ireland
• Information provided by (Responsible Party): Pam Zeitlin, National Jewish Health

Study Description

Brief Summary:

We propose to test the effectiveness of the combination of CF pancreatic enzyme replacement therapy (PERT) on absorption of Ravicti® and subsequent restoration of nasal epithelial cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride transport during the nasal potential difference (NPD) test. Funding source FDA Office of Orphan Products Development.

Condition or disease	Intervention/treatment	Phase
Cystic Fibrosis	Drug: Ravicti low dose; Drug: Ravicti high dose; Drug: Placebo	Phase 1; Phase 2

Detailed Description:

We were the first to test 4-phenylbutyrate (Buphenyl) as a systemic corrector of these defects in F508del under an investigator-initiated Investigational New Drug (IND)application held by P. Zeitlin. In a series of Phase 1 and 2 trials we established the maximum tolerated dose as 20 gm daily divided t.i.d. and the maximum induction of cyclic AMP (cAMP)-mediated nasal epithelial chloride transport with 30 gm daily as a median of -10 millivolt (mV) on days 4 and 7 of treatment.1;2 Under those conditions there was no significant decrease in sweat chloride values or in amiloride-inhibited nasal potential difference (NPD). We interpreted these results as a proof of concept of corrector therapy, but corrector therapy alone was likely an insufficient therapy for this mutation in CF, and therefore closed the IND for 4-phenylbutyrate.

In the ensuing years, Vertex Pharmaceuticals, Inc. has had success with the development of ivacaftor3;3;4 (VX-770) as a potentiator of G551D CFTR and has studied the drug alone and in combination with their corrector lumacaftor5 (VX-809) and VX-661. We at Johns Hopkins University (JHU), University of Alabama at Birmingham (UAB) and Childrens' Hospital of Philadelphia/University of Pennsylvania (CHOP/Penn) have participated in many of the clinical trials and are pleased and encouraged by the success of VX-770. It is not yet certain that future combinations of corrector(s) and potentiator(s) will be safe and effective, and it is prudent to explore alternative correctors and potentiators. Furthermore, recent structural investigations in a number of laboratories support the idea that more than one corrector may be necessary to fully restore F508del to the trafficking pathway 6. Precedent for combination of 4PBA with other CFTR modulators has been established in vitro 7;8 4-Phenylbutyrate tablets are formulated for oral delivery, and we showed that the pharmacokinetics were similar in CF to that in patients with urea cycle disorders. However the large number of tablets that had to be ingested at each meal were somewhat daunting at the 30 gm daily dose. A new pro-drug of 4-phenylbutyrate, glycerol phenylbutyrate or Ravicti®(owned by Hyperion Pharmaceuticals, Inc.) was approved in February 2013 by the US FDA. This new formulation is a significant advance for patients with urea cycle disorders because it is an oral, odorless, tasteless liquid, that contains 3 molecules of 4-phenylbutyrate for every molecule of the triglyceride. Simple arithmetic would suggest that one mole equivalent of the pro-drug provides three moles of active drug. However, pancreatic lipase enzymes are required to break the covalent bonds and release the active drug in the intestines. Because most CF patients homozygous for F508del are pancreatic-insufficient and already on enzyme therapy, we propose to test the effectiveness of the combination of CF pancreatic enzyme replacement therapy (PERT) on absorption of Ravicti® and subsequent restoration of nasal epithelial CFTR-mediated chloride transport during the nasal potential difference (NPD) test.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 36 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis
• Actual Study Start Date: December 2, 2018
• Estimated Primary Completion Date: June 30, 2021
• Estimated Study Completion Date: June 30, 2021

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Ravicti low dose; Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.	Drug: Ravicti low dose; 8 am, 4pm and midnight; Other Name: Ravicti, glycerol phenylbutyrate
Active Comparator: Ravicti high dose; Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.	Drug: Ravicti high dose; 8 am, 4pm and midnight; Other Name: Ravicti, glycerol phenylbutyrate
Placebo Comparator: Placebo; Matching placebo taken at 8am, 4pm and midnight for 7 days.	Drug: Placebo; 8 am, 4pm and midnight

Outcome Measures

Primary Outcome Measures :

1. The primary biological endpoint will be the change in average measurement of nasal potential difference between day 7 and baseline. [ Time Frame: 7 days ]
   chloride and sodium transport in nasal epithelium

Secondary Outcome Measures :

1. Change in other NPD measures from baseline and Days 4, 7, and 14 to include baseline PD, change in amiloride, low chloride, and low chloride plus isoproterenol. [ Time Frame: 14 days ]
   change between date and baseline in sodium and chloride transport
2. Change in average sweat chloride measurement between days 4, 7, 14 and baseline. [ Time Frame: 14 days ]
   change between study time point and baseline in sweat chloride
3. Safety and tolerability. [ Time Frame: 14 days ]
   standard safety and tolerability lab values
4. Efficacy of PERT on absorption of Ravicti®. [ Time Frame: 14 days ]
   quantification of exogenous pancreatic enzyme effects on release of active drug from the pro-drug triglyceride form

Other Outcome Measures:

1. Plasma will be sampled for pharmacokinetics (PK) studies [ Time Frame: 14 days ]
   blood pharmacokinetics
2. Safety labs: hematology, complete metabolic panel (CMP), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), uric acid. Sputum microbiology and spirometry will be performed. [ Time Frame: 14 days ]
   blood counts, metabolic measures, CRP

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female 18 years or older.
2. Confirmed diagnosis of CF based on the following criteria:

any CFTR genotype combination EXCEPT two stop codons and one or more clinical features consistent with the CF phenotype 3. Taking pancreatic enzyme replacement therapy (PERT). 4. Ability to perform acceptable spirometry. 5. Ability to understand and sig a written informed consent and comply with the requirements of the study.

6 FEV1 greater than 30% predicted normal for age, gender, height (Hankinson standards) pre or post-bronchodilator at Screening.

7. Oxygen saturation by pulseoximetry 90% or greater breathing ambient air or regular oxygen regimen at screening and day 1.

8. Hematology and clinical chemistry of blood and urine results with no clinically significant abnormalities that would interfere with the study assessments (as judged by the principal investigator) at screening. If electrolyte abnormality at screening, values must be corrected prior to dosing.

9. Subjects on chronic inhaled antibiotic therapy are eligible if they can continue their usual antibiotic regimen, or remain on their off-cycle period, for the duration of study drug exposure.

10. Negative pregnancy test for women of child-bearing potential. 11. If of childbearing potential, agree to use one highly effective method of contraception from the time of consent through the Visit 4 study visit, per section 9.1.13 of the protocol.

Exclusion Criteria:

1. Current use of ivacaftor (Kalydeco), lumacaftor/ivacaftor combination, or other corrector or potentiator (Symdeko) less than 30 days from Screening.

2 Any investigational drug or device within 30 days of Screening or within 6 half-lives of the investigational drug (whichever is longer).

3. History of any illness or condition that in the opinion of the investigator could confound the results of the study or pose additional risk to subjects.

4. Any change in chronic therapies for CF lung disease (e.g., Ibuprofen, Pulmozyme®, hypertonic saline, Azithromycin, TOBI®, Cayston®) within 4 weeks of Study Day 1 5. Pregnant, planned pregnancy or breast feeding 6. Clinically significant cardiac, liver or kidney disease 7. Seizure disorder 8. Acute upper respiratory infection within 2 weeks or acute pulmonary exacerbation requiring intravenous antibiotics within 4 weeks of Screening Visit 9. Sinus surgery within 6 weeks of Screening Visit 10. Abnormal renal function 11. Abnormal liver function, defined as ≥3x upper limit of normal (ULN) of aspartate aminotransferase (AST), alanine aminotransferase (ALT) or known cirrhosis.

12. Screening laboratory results which in the judgment of the investigator would interfere with completion of the study 13. History of or listed for solid organ or hematological transplantation

Contacts and Locations

Contacts

Contact: Jennifer Brandorff; 303-398-1811; brandorffJ@NJHealth.org

Contact: Britany Zeglin, BS; 443-287-8983; bzeglin1@jhmi.edu

Locations

United States, Alabama

University of Alabama at Birmingham; Not yet recruiting

Birmingham, Alabama, United States, 35294-0006

Contact: Steven M Rowe, MD, MSPH 205-934-9640 smrowe@uab.edu

Principal Investigator: Steven M Rowe, MD, MSPH

United States, Colorado

National Jewish Health; Recruiting

Denver, Colorado, United States, 80206

Contact: Connie StClair 303-270-2321 shiven@njhealth.org

Principal Investigator: Noah Lechtzin, MD

Sub-Investigator: Peter Mogazel, MD, PhD

United States, Pennsylvania

Children's Hospital of Philadelphia; Not yet recruiting

Philadelphia, Pennsylvania, United States, 19104

Contact: Ron Rubenstein, MD, PhD 215-590-1281 rrubenst@mail.med.upenn.edu

Principal Investigator: Ron Rubenstein, MD, PhD

Sponsors and Collaborators

National Jewish Health

University of Alabama at Birmingham

Children's Hospital of Philadelphia

Johns Hopkins University

Horizon Pharma Ireland, Ltd., Dublin Ireland

Investigators

• Principal Investigator: Pamela L Zeitlin, MD, PhD; National Jewish Health

More Information

Additional Information:

Johns Hopkins CF research office 

• Responsible Party: Pam Zeitlin, Professor of Pediatrics, National Jewish Health
• ClinicalTrials.gov Identifier: NCT02323100 History of Changes
• Other Study ID Numbers: GPBA; FD-R-0005380 ( Other Grant/Funding Number: FDA Office of Orphan Products Development )
• First Posted: December 23, 2014
• Last Update Posted: July 15, 2019
• Last Verified: July 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pam Zeitlin, National Jewish Health:

cystic fibrosis; corrector; glycerol phenylbutyrate; nasal potential difference

Additional relevant MeSH terms:

Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases; 4-phenylbutyric acid; Glycerol; Cryoprotective Agents; Protective Agents; Physiological Effects of Drugs; Antineoplastic Agents